XENE · Insider Trading
Xenon Pharmaceuticals Inc
Every open-market purchase and sale reported by XENE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Thomas Patrick Kelly | Chief Financial Officer | M | +7,500 | — |
| 2026-10-01 | Thomas Patrick Kelly | Chief Financial Officer | Buy | +15,000 | +$559.74K |
| 2026-10-01 | Ian Mortimer | PRESIDENT & CEO | Buy | +30,000 | +$1.12M |
| 2026-09-03 | Dawn Svoronos | Director | M | +5,144 | +$41.92K |
| 2026-08-31 | Christopher John Kenney | Chief Medical Officer | Sell | −7,068 | −$425.83K |
| 2026-08-13 | Steven Gannon | Director | Sell | −10,000 | −$640.55K |
| 2026-06-08 | Gillian Cannon | Director | Sell | −1,190 | −$63.24K |
| 2026-06-08 | Gary Patou | Director | Sell | −1,322 | −$70.25K |
| 2026-06-03 | Steven Gannon | Director | MIXED | +1,229 | −$75.63K |
| 2026-06-03 | Patrick Machado | Director | M | +2,645 | — |
| 2026-06-03 | Elizabeth A. Garofalo | Director | M | +2,645 | — |
| 2026-06-03 | Gillian Cannon | Director | M | +2,645 | — |
| 2026-06-03 | Justin D. Gover | Director | M | +2,645 | — |
| 2026-06-03 | Dawn Svoronos | Director | MIXED | +1,229 | −$75.63K |
| 2026-06-03 | Gary Patou | Director | M | +2,645 | — |
| 2026-05-13 | Steven Gannon | Director | M | +3,500 | +$25.83K |
| 2026-03-13 | Christopher John Kenney | Chief Medical Officer | MIXED | +2,340 | −$77.87K |
| 2026-03-13 | Andrea DiFabio | Chief Legal Officer | MIXED | +2,408 | −$74.11K |
| 2026-03-13 | Ian Mortimer | PRESIDENT & CEO | MIXED | +5,192 | −$403.58K |
| 2026-03-11 | Andrea DiFabio | Chief Legal Officer | MIXED | +4,893 | −$156.70K |
| 2026-03-11 | Christopher John Kenney | Chief Medical Officer | MIXED | +4,729 | −$166.56K |
| 2026-03-11 | Ian Mortimer | PRESIDENT & CEO | MIXED | +8,731 | −$15.15M |
| 2026-01-09 | Darren S Cline | Chief Commercial Officer | A | +60,000 deriv. | — |
| 2026-01-09 | Christopher John Kenney | Chief Medical Officer | A | +120,000 deriv. | — |
| 2026-01-09 | Ian Mortimer | PRESIDENT & CEO | A | +415,000 deriv. | — |
| 2026-01-09 | Andrea DiFabio | Chief Legal Officer | A | +95,000 deriv. | — |
| 2026-01-02 | Ian Mortimer | PRESIDENT & CEO | MIXED | — | −$1.48M |
| 2025-12-09 | Ian Mortimer | PRESIDENT & CEO | Sell | −25,205 | −$1.14M |
| 2025-12-03 | Ian Mortimer | PRESIDENT & CEO | Sell | −97 | −$4.37K |
| 2025-10-17 | Thomas Patrick Kelly | Chief Financial Officer | A | +255,000 deriv. | — |
| 2025-10-01 | Ian Mortimer | PRESIDENT, CEO & INTERIM CFO | MIXED | — | −$811.75K |
| 2025-06-24 | Darren S Cline | Chief Commercial Officer | A | +185,800 deriv. | — |
| 2025-06-06 | Patrick Machado | Director | A | +19,657 deriv. | — |
| 2025-06-06 | Steven Gannon | Director | Sell | −3 | −$91 |
| 2025-06-06 | Dawn Svoronos | Director | A | +19,657 deriv. | — |
| 2025-06-06 | Elizabeth A. Garofalo | Director | A | +19,657 deriv. | — |
| 2025-06-06 | Gillian Cannon | Director | A | +19,657 deriv. | — |
| 2025-06-06 | Gary Patou | Director | A | +19,657 deriv. | — |
| 2025-06-06 | Justin D. Gover | Director | A | +19,657 deriv. | — |
| 2025-05-16 | Steven Gannon | Director | M | +5,144 | +$64.66K |
| 2025-03-13 | Christopher John Kenney | Chief Medical Officer | A | +95,000 deriv. | — |
| 2025-03-13 | Ian Mortimer | PRESIDENT & CEO | A | +325,000 deriv. | — |
| 2025-03-13 | Andrea DiFabio | Chief Legal Officer | A | +95,000 deriv. | — |
| 2025-01-27 | Ian Mortimer | PRESIDENT & CEO | MIXED | — | −$1.24M |
| 2024-12-19 | Sherry Aulin | Chief Financial Officer | MIXED | — | −$771.00K |
| 2024-11-22 | Gary Patou | Director | MIXED | — | −$200.98K |
| 2024-06-05 | Gillian Cannon | Director | A | +15,542 deriv. | — |
| 2024-06-05 | Dawn Svoronos | Director | A | +15,542 deriv. | — |
| 2024-06-05 | Gary Patou | Director | A | +15,542 deriv. | — |
| 2024-06-05 | Justin D. Gover | Director | A | +15,542 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ian Mortimer | PRESIDENT & CEO | 64,223 | $2.33M |
| Dawn Svoronos | Director | 31,373 | $1.14M |
| Gary Patou | Director | 29,798 | $1.08M |
| Thomas Patrick Kelly | Chief Financial Officer | 22,500 | $817.76K |
| Andrea DiFabio | Chief Legal Officer | 8,643 | $314.13K |
| Sherry Aulin | Chief Financial Officer | 7,199 | $261.65K |
| Patrick Machado | Director | 2,645 | $96.13K |
| Justin D. Gover | Director | 2,645 | $96.13K |
| Elizabeth A. Garofalo | Director | 2,645 | $96.13K |
| Steven Gannon | Director | 1,870 | $67.97K |
| Gillian Cannon | Director | 1,455 | $52.88K |
| Christopher John Kenney | Chief Medical Officer | 702 | $25.51K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XENE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.